The purpose of this phase I trial is to evaluate dose-limiting toxicity while dose escalating single-fraction preoperative S-PBI to a presumed radioablative dose over 3 cohorts, starting with 30Gy in 1 fraction and advancing to 34Gy and 38Gy in 1 fraction.
Recruiting
Phase 1
Preoperative stereotactic breast radiation may be beneficial as it offers the ability to
target smaller treatment volumes than what has been achievable with adjuvant PBI (Nichols
IJROBP 2010), track radiobiological response to radiation at time of surgical pathology, and
allow the removal of all irradiated tissue to potentially minimize late effects.The purpose
of this phase I trial is to evaluate dose-limiting toxicity while dose escalating
single-fraction preoperative S-PBI to a presumed radioablative dose over 3 cohorts, starting
with 30Gy in 1 fraction and advancing to 34Gy and 38Gy in 1 fraction. This would be
accomplished on the CyberKnife or GammaPod. The GammaPod is a novel device dedicated to S-PBI
utilizing a Cobalt-60 source (Yu Med Phys 2013), which offers a highly reproducible prone
setup with a mean of 1.8mm of mismatch reported in 15 patients at the University of Maryland
on consecutive scans (Yu JCO 2011). Implications of this research are far reaching, including
determination of the maximally tolerated dose for preoperative S-PBI, pathologic complete
response rates of early stage breast cancer to a predicted radioablative dose, radiographic
markers of treatment response (radiomics), and translational research assessing mechanisms of
immune and radiation response.
| Name | Type | Description | Interventions |
|---|---|---|---|
| Single-fraction stereotactic partial breast radiotherapy | Experimental | The primary objective is to escalate the dose of 1 fraction stereotactic partial breast radiotherapy utilizing the MR Linac,Gammapod or Cyberknife system to an ablative dose in the pre-operative setting to the primary tumor without exceeding the maximum tolerated dose in patients with early stage breast cancer. |
Inclusion Criteria:
1. Invasive epithelial (ductal, medullary, lobular, papillary, mucinous (colloid), or
tubular) histologies of the breast 3 cm or less(T1-T2cN0) in women who have not
undergone surgery or neoadjuvant endocrine or chemotherapy for current breast cancer
diagnosis
2. Tumor must not involve the overlying skin based on imaging evaluation and/or clinical
exam
3. Age >/= 18 years old and female
4. Greatest Tumor dimension is 3cm or less based on US. MRI measurements can be included
only if performed BEFORE the biopsy
5. Tumor must be unifocal
6. The tumor must be visible on CT scan and/or preferably marked with clip(s) in tumor
7. Patients must undergo an MRI for work up to aid in tumor delineation and to rule out
additional foci of disease. If additional foci of disease are present, they need to
have a negative biopsy to proceed with treatment.If patient cannot have MRI, contrast
enhanced digital mammography (CEDM) is allowed in place of MRI.
8. Clinically and radiographically node negative on ultrasound of the axilla or MRI
9. Estrogen receptor positive or Progesterone receptor positive and Her2neu negative
10. Ability to understand and the willingness to sign a written informed consent.
11. Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to the start of study
and for the duration of radiation therapy. Should a woman become pregnant or suspect
she is pregnant while participating in this study, she should inform her treating
physician immediately
A female of child-bearing potential is any woman (regardless of sexual orientation, having
undergone a tubal ligation, or remaining celibate by choice) who meets the following
criteria:
- Has not undergone a hysterectomy or bilateral oophorectomy; or
- Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has
had menses at any time in the preceding 12 consecutive months
Exclusion Criteria:
1. Multi-centric disease
2. Prior RT to the involved breast
3. Tumor size >3cm
4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that, in the opinion of the
investigator, would limit compliance with study requirements
5. Patients who are pregnant or lactating due to the potential exposure to the fetus to
radiation therapy and unknown effects of radiation therapy to lactating females
6. Patients unable to have an MRI or contrast enhanced digital mammography (CEDM)
7. Prior ipsilateral breast cancer
8. Tumor less than 5mm from the skin surface on clinical exam and/or radiographic imaging
9. Patients with active Lupus or scleroderma
| Maximum Eligible Age: | N/A |
| Minimum Eligible Age: | 18 Years |
| Eligible Gender: | Female |
| Healthy Volunteers: | No |
| Measure: | Reach the maximum tolerated dose (MTD) or a dose of 38 Gy total |
| Time Frame: | 5 years |
| Safety Issue: | |
| Description: | Done by escalating the dose of SBRT toward the tumorcidal dose of 38 Gy in fraction. Doses will be escalated an additional 3.5-4 Gy per treatment. The phase I portion of the study will be completed when either of the following events occur: 1) the MTD for a cohort is reached or 2) when delivery of a pre-determined highest dose of radiation (38 Gy) that has been deemed likely to be efficacious for treatment of early stage breast cancer is attained.Toxicity will be assessed according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE), version 5.0. |
| Phase: | Phase 1 |
| Primary Purpose: | Interventional |
| Overall Status: | Recruiting |
| Lead Sponsor: | University of Texas Southwestern Medical Center |
May 3, 2021
